ArticleInternational journal of retina and vitreous2025
Neovascular age-related macular degeneration complicated by large submacular hemorrhage managed with faricimab monotherapy.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo retrospectively evaluate the visual and anatomic outcomes of intravitreal faricimab monotherapy in treatment naïve neovascular age-related macular degeneration (nAMD) patients presenting with large submacular hemorrhage (SMH).
methodsPatients with neovascular age-related macular degeneration (nAMD) presenting with at least 50% subretinal hemorrhage (SRH) involving the fovea between March 2023 and June 2025 were identified. Patients with greater than 750 microns of total thickness of subfoveal hemorrhage were excluded. Patients were treated with faricimab as first line therapy utilizing a treat-extend-stop protocol for one year. Spectral domain optical coherence tomography (SD-OCT) and fluorescein angiogram (FA)/ indocyanine green angiography (ICG) were used to determine total CNV lesion size, SRH area size, and macular thickness. Visual acuity and SD-OCT were also obtained at each visit.
resultsSix patients were identified that met the inclusion criteria. There were two males and four females. The average age of was 83.0 years. Prior to treatment, the average total CNV lesion size was 19.7mm2 and the average hemorrhage area was 14.5 mm2 for an average SRH percentage of 73.8%. The average central macular thickness (CMT) prior to treatment was 478.3 μm and the average CMT 6 months after beginning treatment was 306.8 μm (p = 0.0031). The average CMT 1 year after treatment was 259.0 μm (p = 0.0017). Average ETDRS letters before treatment was 48.8 letters {Snellen equivalent 20/138} with a range of 23–70 letters. Average ETDRS letters after 6 months of treatment was 60.3 letters {Snellen equivalent 20/63} with a range of 42 to 76 letters (p = 0.017). Average ETDRS letters after 1 year of treatment was 64.7 letters {Snellen equivalent 20/50} with a range from 26 to 80 letters (p < 0.014). The average number of injections was 9.3 at 1 year.
conclusionIn patients with nAMD complicated by at least 50% SRH, there was improved vision and decreased CMT. On average, vision improved by 16.4 ETDRS letters and improved on average from 20/138 to 20/50 on Snellen after 1 year of faricimab monotherapy. These patients may be successfully managed with faricimab monotherapy. While visual acuity overall improved, some patients had more improvement than others likely due to the location of the CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.